Business
Phase 1b/2a Program Commences for RVX-208
TSX Exchange Symbol: RVX CALGARY, Aug. 25 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Compan...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, Aug. 25 /CNW/ - Resverlogix Corp. ("Resverlogix" or the\n"Company") (TSX:RVX) is pleased to announce that the Phase 1b/2a program for\nthe study of RVX-208 in subjects with normal lipids and those with low\nhigh-density lipoprotein (HDL) cholesterol has proceeded according to plan.\n\n\n"We are very excited about moving forward into this important 28-day\nstudy with RVX-208. Our previous clinical study demonstrated that RVX-208 was\nsafe, tolerable and had favorable pharmacokinetics," stated Dr. Allan Gordon,\nSenior Vice President Clinical Development of Resverlogix. "This trial will\ncontinue to examine safety and tolerance as well it is a proof of principle\nstudy for ApoA-I production and HDL functionality. Approximately half of the\nsubjects will have low levels of HDL cholesterol, a condition associated with\nsignificant increased risk of cardiovascular disease," added Dr. Gordon.\n\n\n"The ensuing Phase 1b/2a study comprises several novel facets to expedite\nthe clinical process for RVX-208 and its eventual registration as a drug,"\nstated Donald J. McCaffrey, President and CEO of Resverlogix. McCaffrey\nfurther confirmed, "Along with the required regulatory provisions that must be\naddressed such as safety, tolerance and pharmacokinetics, the study also will\nmeasure key reverse cholesterol transport markers which RVX-208 impacts. These\nare exclusive favorable features that make this drug unique among its\ncompetitors."\n\n\nRVX-208, a novel small molecule therapeutic that facilitates endogenous\nApoA-I production, is positioned to be one of the most promising emerging\ndrugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208\nis the only novel small molecule that is specifically designed to increase\nApoA-I production and thereby raise HDL levels thus enhancing HDL\nfunctionality to augment reverse cholesterol transport.\n\n\nAbout Resverlogix Corp.\n\n\nResverlogix Corp. is a leading biotechnology company engaged in the\ndevelopment of novel therapies for important global medical markets with\nsignificant unmet needs. The NexVas(TM) program is the Company's primary focus\nwhich is to develop novel small molecules that enhance ApoA-I. These vital\ntherapies address the grievous burden of ather...